Pasar al contenido principal

PAPEL DE LA CICLOOXIGENASA-2 EN EL DAÑO POR ISQUEMIA/REPERFUSION EN EL HIGADO. ESTUDIO DE LA FUNCION MITOCONDRIAL

SAF2016-75004-R

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2016
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Role of COX-2 in liver mitochondrial function

  • Fuertes-Agudo, Marina
  • Cucarella, Carme
  • Brea, Rocío
  • Casanova, Natalia
  • Boscá, Lisardo
  • Martín-Sanz, Paloma
  • Casado, Marta
Póster presentado al 42nd Congress of the Spanish Society of Biochemistry and Molecular Biology (SEBBM), celebrado en Madrid del 16 al 19 de julio de 2019., Liver and heart are two principal organs in the body. Although their physiology is extremely different, both tissues have in common that adult hepatocytes and cardiomyocytes fail to induce COX-2 expression, the key enzyme in the synthesis of prostaglandins, regardless of the pro-inflammatory factors used. In both cell types, COX-2 expression is restricted to those situations in which dedifferentiation or proliferation occur. In parallel studies, using mice genetically modified to selectively express hCOX-2 in hepatocytes and cardiomyocytes, we have demonstrated an increased tolerance to ischemia-reperfusion injury (IRI) with an increased functional recovery, a diminished cellular necrosis and less inflammation. It is known that mitochondria have a major role in IRI damage by increasing oxidative stress, decoupling metabolic state and inducing apoptosis. In this work, we analyse different aspects in order to characterize the impact of COX-2 in mitochondrial function., SAF2016-75004-R and BES-2017-081928, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Cyclooxygenase-2 expression in hepatocytes protects against hepatic ischemia/reperfusion injury in mice

  • Motiño, Omar
  • Francés, Daniel E.
  • Casanova, Natalia
  • Cucarella, Carme
  • Fuertes-Agudo, Marina
  • Flores, Juana María
  • Olmedilla, Luis
  • Pérez Peña, José
  • Bañares, Rafael
  • Boscá, Lisardo
  • Casado, Marta
  • Martín-Sanz, Paloma
Trabajo presentado al 41 Congreso de la Sociedad Española de Bioquímica y Biología Molecular (SEBBM), celebrado en Santander del 10 al 13 de septiembre de 2018., Liver ischemia and reperfusion injury (IRI) remains a serious clinical problem affecting liver transplantation outcomes. IRI causes up to 10% of early organ failure and predisposes to chronic rejection. Cyclooxygenase-2 (COX-2) is involved in different liver diseases but the significance of COX-2 in liver IRI is a matter of controversy. This study was designed to elucidate the role of COX-2 expression in hepatocytes in the pathogenesis of liver IRI. In the present work hepatocyte-specific COX-2 transgenic mice (hCOX-2-Tg) and their wild-type (Wt) littermates were subjected to partial IRI and the results show that hCOX-2-Tg exhibited lower grades of necrosis and inflammation than Wt mice in part by reduced recruitment and infiltration of hepatic macrophages and netrophils with a corresponding decrease in serum levels of pro-inflammatory cytokines. Moreover hCOX-2-Tg mice showed a significant attenuation of the IRI-induced increase in oxidative stress and hepatic apoptosis an increase in autophagic flux and a decrease in endoplasmic reticulum (ER) stress comparing with that observed in Wt mice. Preconditioning of Wt mice resembles the beneficial effects of hCOX-2-Tg mice in IRI due to an increase in endogenous COX-2 expression. Furthermore measurement of PGE2 levels in plasma from patients who underwent orthotopic liver transplantation revealed a significantly negative correlation between PGE2 levels and graft function and time of ischemia. Overall the data support the view of the beneficial effects of hepatic COX-2 dependent prostaglandins after liver IRI., This work was supported by i‐COOP2016‐20213 (CSIC) to D.F., P.M.S; SAF2014‐52492 (MINECO, Spain) to L.B.; CIBERcv and CIBERehd (ISCIII, Spain) to L.B., P.M.S and M.C.; SAF2016‐75004‐R (MINECO, Spain) to P.M.S. and M.C. M F‐A. is recipient of FPI fellowship from MINECO (BES‐2017‐081928)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Role of cyclooxygenase 2 (COX-2) in liver mitochondrial function after ischemia-reperfusion injury

  • Fuertes-Agudo, Marina
  • Cucarella, Carme
  • Brea, Rocío
  • Boscá, Lisardo
  • Martín-Sanz, Paloma
  • Casado, Marta
Póster presentado al: Liver Meeting AASLD 2021: American Association fort eh Study of Liver Diseases. (Anaheim, CA, USA and virtual), 12-15 de novembre 2021 Abstract: 470, pag. 293A, In this work, we analyzed different aspects in order to characterize the impact of COX-2 in mitochondrial function after IRI., This work was supported by SAF2016-75004-R (MINECO, Spain) and PID2019-108977RB-I00 (MICINN, Spain), CIBERehd (ISCIII, Spain). M F-A. is recipient of FPI fellowship from MINECO (BES-2017-081928), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Liver spheroids: a robust human in vitro system for testing the therapeutic options of cyclooxygenase 2 in NAFLD/NASH

  • Fuertes-Agudo, Marina
  • Brea, Rocío
  • Luque-Tévar, María
  • Cucarella, Carme
  • Martín-Sanz, Paloma
  • Casado, Marta
Trabajo presentado en el FASEB Science Research Conference: The Liver Biology Conference: Fundamental Mechanisms and Translational Applications,, [Background]: NAFLD is the most prevalent chronic liver disease in the world and is considered the hepatic manifestation of metabolic syndrome. It begins with an accumulation of fat in the liver, which can lead to cellular damage and inflammation (NASH) and, if unaddressed, progresses to liver fibrosis, where parenchymal tissue is replaced by extracellular matrix. Cyclooxygenase (COX) is a key regulatory step in the biosynthesis of prostanoids. The COX-2 isoform is expressed and induced by different stimuli in various tissues and cell types; however, in liver, COX-2 expression is restricted to those situations in which proliferation or dedifferentiation occur (1). Our previous results revealed that COX-2 expression in hepatocytes protects against hyperglycemia-induced liver damage and against peripheral insulin resistance and adiposity in mice subjected to a high-fat diet (2). Furthermore, COX-2 expression in hepatocytes protects against experimental nonalcoholic steatohepatitis and fibrosis in mice (3). [Aims]: Since our previous results are performed in mice, we wanted to bridge from animal models to a more translational research, close to human. Therefore, we wanted to establish an in vitro model based on 3D human cell culture to evaluate the role of COX-2, specifically the role of prostaglandins, in a human model of NAFLD/NASH. [Methods]: To analyze the role of COX-2 in steatosis and fibrosis, we established a 3D spheroid culture composed of HepG2 and LX-2 cells. These spheroids were treated with palmitic acid and TGF¿ to induce NAFLD/NASH and fibrosis, respectively. They were then treated with PGE2 to evaluate their effect in this model. [Results]: In summary, our results demonstrate that PGE2 treatment reduces lipid levels after fatty acid exposure. Moreover, it reduces fatty acid-induced cell damage and insulin resistance. Furthermore, PGE2 slows fibrotic progression by decreasing stellate cells activation after TGF¿ stimulation. Conclusions: These preliminary results indicate that a therapeutic strategy for the treatment of NAFLD/NASH may be COX-2-derived prostaglandin therapy., This work was supported by SAF2016-75004-R and PID2019-108977RB-I00 (MINECO, Spain) and CIBERehd (ISCIII, Spain). M F-A. and M L-T are recipient of FPI fellowship from MINECO (BES-2017-081928 and PRE2020-094885, respectively). We thank FEDER for financial support.